FDA ap­proves Ipsen’s Onivyde as first-line treat­ment for type of pan­cre­at­ic can­cer

The FDA on Tues­day ap­proved Ipsen’s can­cer drug Onivyde as the first-line treat­ment for a type of pan­cre­at­ic can­cer, to be used along­side oth­er can­cer med­ica­tions.

The ap­proval of Onivyde (irinote­can li­po­some) is based on pos­i­tive re­sults from the com­pa­ny’s NAPOLI 3 tri­al, which eval­u­at­ed 770 pa­tients with metasta­t­ic pan­cre­at­ic ade­no­car­ci­no­ma who had not pre­vi­ous­ly re­ceived chemother­a­py for their metasta­t­ic dis­ease. The tri­al showed that Onivyde ex­tend­ed pa­tients’ lives two months longer than the cur­rent stan­dard of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER